[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fmt\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fmt":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100649410","phase-4-fecal-microbiota-transplantation-for-type-2-diabetes-mellitus-and-hashimotos-thyroiditis-100649410",false,"NCT07733232","Fecal Microbiota Transplantation for Type 2 Diabetes Mellitus and Hashimoto's Thyroiditis","Efficacy of Fecal Microbiota Transplantation in Improving Metabolic Parameters and Immune Dysregulation in Patients With Concurrent Type 2 Diabetes Mellitus and Autoimmune Thyroid Disease.","Inclusion Criteria:\n\n1. Age ≥ 18 and ≤ 65 years old.\n2. Diagnosed with type 2 diabetes mellitus (T2DM).\n3. Positive for thyroid peroxidase antibody (TPOAb) and thyroglobulin antibody (TgAb); thyroid ultrasonography indicates diffuse thyroid lesions.\n4. The regimens of hypoglycemic drugs and thyroid-related basic treatments (including drug types and dosages) have remained stable for at least 3 months before enrollment.\n\nExclusion Criteria:\n\n1. Subjects who have used antibiotics, probiotics or prebiotics within 4 weeks prior to screening.\n2. Patients complicated with severe gastrointestinal diseases (e.g., inflammatory bowel disease, active gastrointestinal bleeding).\n3. Patients receiving specialized treatment for hyperthyroidism (Graves' disease) or with a history of thyroid malignancy.\n4. Patients with severe immunosuppression (neutrophil count \\\u003C 1500\u002Fmm³, lymphocyte count \\\u003C 500\u002Fmm³).\n5. Patients with active severe gastrointestinal bleeding, intestinal perforation, or severe intestinal barrier\u002Fmucosal injury.\n6. Patients with intestinal mucosal injury of unknown etiology.\n7. Patients diagnosed with fulminant colitis or toxic megacolon.\n8. Patients with active extraintestinal infection requiring treatment with broad-spectrum antibiotics.\n9. Severe malnutrition (body mass index \\\u003C 15 kg\u002Fm²) or severe hypoalbuminemia (serum albumin \\\u003C 25 g\u002FL).\n10. Congenital or acquired immunodeficiency diseases.\n11. Patients who have recently received high-risk immunosuppressants or cytotoxic drugs (e.g., rituximab, doxorubicin), or medium-to-high dose glucocorticoids (e.g., prednisone \\>= 20 mg per day for more than 4 consecutive weeks).\n12. Patients complicated with other autoimmune diseases.\n13. Patients with severe hepatic or renal insufficiency.\n14. Patients with malignant tumors.\n15. Patients with known allergy to capsule ingredients.\n16. Pregnant or lactating females.","ALL","18 Years","65 Years",{"count":20,"type":21},38,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of this clinical trial is to learn if fecal microbiota transplantation (FMT) can improve metabolic control and immune function in adults with both type 2 diabetes and Hashimoto's thyroiditis (an autoimmune thyroid disease). It will also learn about the safety of FMT in these patients. The main questions it aims to answer are:\n\nCan FMT lower blood sugar levels (HbA1c, fasting blood glucose, and 2-hour post-meal blood glucose) in participants with type 2 diabetes? Can FMT reduce thyroid autoantibody levels (TPOAb and TgAb) in participants with Hashimoto's thyroiditis? This is a single-arm study, meaning all participants will receive the same FMT treatment. Researchers will compare each participant's results before and after the intervention to see if FMT has an effect.\n\nParticipants will:\n\nComplete baseline tests including blood work and stool sample collection during the 2-week screening period Take 40 oral FMT capsules by mouth over about 1.5 hours under medical supervision at the start of the study Keep taking their usual diabetes and thyroid medications at the same dose throughout the study, unless their doctor says otherwise Return for follow-up visits and tests at 12 weeks and 24 weeks after the FMT treatment",[27,28,29],"Autoimmune Thyroid Disease","Type 2 Diabetes Mellitus (T2DM)","FMT","NOT_YET_RECRUITING","2026-07-23",{"date":33,"type":34},"2026-07-29","ACTUAL",{"date":36,"type":21},"2026-08",{"date":38,"type":21},"2027-12",{"name":40,"class":41},"Shen Xujun","OTHER_GOV",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":71},"100628234","phase-3-fmt-capsules-for-rcdi-100628234","NCT07458984","FMT Capsules for rCDI","Fecal Microbiota (FMT) Oral Capsules in the Treatment of Recurrent Clostridioides Difficile Infection","FMT CAP CDI","Inclusion Criteria:\n\n* At least twice recurrent CDI\\*\n* Patient has had CDI-related diarrhea during infections (3 or more Bristol Stool Form Scale type 6-7 stools)\n* Other causes of diarrhea have been excluded based on clinical data\n* Age over 18 years\n* Remission of symptoms during antibiotic course (metronidazole, vancomycin or fidaxomicin)\n* No other antibiotic courses\n* Able to sign the consent form or accept it electronically via Suomi.fi identification\n\n  * definition of recurrent CDI: CDI-compatible symptoms and a positive stool test Clostridioides difficile nucleic acid test within 12 weeks of the previous infection\n\nExclusion Criteria:\n\n* Pregnancy\n* Continuous need for antibiotic treatment\n* Previous anaphylactic reactions to any food\n* Gastroparesis\n* Life-threatening fulminant CDI\n* Life expectancy less than 1 year\n* Inability to sign a consent form for the study",{"count":51,"type":21},76,[53],"PHASE3","Double blind RCT study of tretment of recurrent Clostridioides difficile infection by FMT capsules.",[56,29],"Clostridioides Difficile Infection Recurrence",[58,29,59],"Clostridioides Difficile infection","Capsule","RECRUITING","2026-04-24",{"date":63,"type":34},"2026-04-29",{"date":65,"type":34},"2026-04-25",{"date":67,"type":21},"2030-12-31",{"name":69,"class":70},"Helsinki University Central Hospital","OTHER",1,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":71},"100502342","phase-2-synbiotics-and-fecal-microbiota-transplantation-to-treat-non-alcoholic-steatohepatitis-100502342","NCT05821010","Synbiotics and Fecal Microbiota Transplantation to Treat Non-Alcoholic Steatohepatitis","SYNCH","Inclusion Criteria:\n\n* biopsy-proven NASH obtained up to 32 weeks before screening: SAF Steatosis score ≥1, Activity ≥2, Fibrosis \\\u003C4; 50% of participants should at least have NASH fibrosis stage 1, 2 or 3 according to the NASH CRN fibrosis staging system based on tandem reading of two expert liver pathologists\n* fluency in Dutch or English\n* participants should be able to understand the information and give informed consent\n\nExclusion Criteria:\n\n* Current or history of significant alcohol consumption for a period of more than 3 consecutive months within 1 year before screening (significant alcohol consumption is defined as more than 2 international units\u002Fday for females and more than 3 international units\u002Fday for males, on average; 1 international unit contains ±14 grams of alcohol)\n* liver cirrhosis or hepatocellular carcinoma\n* hepatitis B and\u002For C\n* auto-immune hepatitis\n* Wilson's disease\n* primary sclerosing cholangitis\n* primary biliary cholangitis\n* alpha-1-antitripsine deficiency and hemochromatosis\n* history of liver transplant, current placement on a liver transplant list\n* use of pre-, pro- or synbiotics\n* use of systemic antibiotics 3 month prior to randomization\n* use of tamoxifen, methotrexate or amiodarone\n* prior or planned bariatric surgery\n* active GLP-1 receptor agonist treated diabetes mellitus\n* bleeding disorder\n* International normalized ratio (INR) of prothrombin time \\>1.4 or platelet count \\\u003C100 109\u002FL at screening\n* anti-platelet\u002Fcoagulant therapy use which cannot be temporarily discontinued\n* any major cardiovascular event within 6 months prior to screening (e.g. myocardial infarction, cerebrovascular accident)\n* prolonged compromised immunity (e.g. recent cytotoxic chemotherapy, HIV-infection with a CD4 count \\\u003C 240)\n* active or prior history of invasive malignancy (except for curatively treated in situ carcinomas \\[e.g., cervix\\] or non-melanoma skin cancer) unless a complete remission was achieved\n* surgery scheduled for the trial duration period, except for minor surgical procedures, in the opinion of the investigator\n* pregnant or nursing women\n* any condition which, in the investigator's opinion, might jeopardize participants' safety or compliance with the protocol\n* participation in another concomitant clinical trial.","75 Years",{"count":81,"type":21},48,[83],"PHASE2","The goal of this clinical trial is to investigate the therapeutic potential of A. soehngenii and pasteurized A. muciniphila combined with B. animalis subsp. lactis and fructo-oligosaccharides with and without conditioned vegan lyophilized fecal microbiota transplantation capsules to reduce NASH in patients with fibrotic NASH. The main questions to answer are:\n\n1. Can NASH be treated by altering the gut microbiota using LFMT capsules?\n2. Can NASH be treated using a syntrophic cocktail of synbiotics and will these strains strengthen the effect of FMT?\n3. What are the underlying mechanism by which the aforementioned treatments attenuate NASH?\n\nParticipants will be treated with FMT-capsules or placebo, and all participants will receive a cocktail of 3 strains of probiotics and one type of prebiotic.",[86,87,88,29,89,90,91,92,93],"Non Alcoholic Steatohepatitis","Non-Alcoholic Fatty Liver Disease","Fecal Microbiota Transplantation","Prebiotics","Probiotics","Microbiome","Intestinal Microbiome","Gut Microbiome","2024-08-26",{"date":96,"type":34},"2024-08-27",{"date":98,"type":34},"2023-03-17",{"date":100,"type":21},"2026-08-20",{"name":102,"class":70},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)"]